Clinical reference on silver toxicity and argyria, including supplement exposure and systemic complications.
Colloidal Silver / Silver Hydrosol
Colloidal Silver / Silver Hydrosol is a supplement, botanical, or biologic intervention discussed for symptom support, inflammation, immune modulation, metabolism, detoxification, or direct anticancer claims depending on the source. In cancer care, it should be evaluated by evidence level, intended use, safety, interactions, and whether it is being used as conventional treatment, supportive care, an experimental adjunct, or an alternative claim.
Patient-facing article stating that colloidal silver is not supported as a cancer treatment and can be toxic; summarizes FDA/legal action context.
Cleveland Clinic consumer article warning not to take colloidal silver internally and summarizing argyria and other risks.
NCCIH states evidence for health claims is lacking, FDA warned colloidal silver is not safe or effective for treating disease, and serious side effects include permanent argyria and drug absorption problems.
MSK monograph: colloidal silver cannot cure cancer, AIDS, or diabetes; no human data support oral use; risks include argyria, seizures, kidney damage, and pregnancy/fetal concerns.
Review of AgNP-based proteogenomics and metabolomics concepts in cancer therapy. Useful for research distinction; not evidence for retail colloidal silver as a cancer protocol.
Preclinical study of silver nanoparticles in triple-negative breast cancer models. Important for claim tracking, but not a clinical endorsement of colloidal silver supplements.
FDA warning letter citing disease claims for colloidal silver products, including cancer-related claims and articles about silver killing cancer cells.
Review of silver nanoparticles, toxicity mechanisms, and potential cancer theranostic applications. Important distinction: this is nanomedicine research, not proof for consumer oral colloidal silver.
Case report of diffuse slate-gray discoloration after colloidal silver ingestion over five years, with biopsy findings and silver particles found in colonic mucosa.
Federal rule states colloidal silver ingredients and silver salts lack adequate data to establish safety and effectiveness for OTC disease treatment/prevention claims.